Loading clinical trials...

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer | Clinical Trials | Clareo Health

RECRUITINGNA

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

NCT07062172•University of California, Irvine

Summary

This is a single-armed screening research study which screens immediate family member of lung cancer patients with a driver mutation to see if lung cancer can be inherited and whether researchers can find lung cancer early. Immediate family members of lung cancer patients will be 40-80 years old and screened using a low dose CT scan.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cohort A:
•Current diagnosis of lung cancer with a driver mutation.
•Known driver mutation (e.g. via NGS, PCR, IHC, FISH, RT-PCR etc.)
•Able and willing to give informed consent.
•Able and willing to complete the screening questionnaire.
•Cohort A:
•Age 40 - 80.
•Must have a first degree relative (mother, father, sibling, biological child) eligible for Cohort A. Note: Multiple first degree relatives of a Cohort A eligible participant may be approached for participation into the trial.
•Smoked \< 20 pack years; a. Pack years = numbers of packs per day × number of years smoked; b. One pack year is the equivalent of smoking an average of 20 cigarettes (1 pack) per day for a year.
•Be able to undergo a low dose chest CT scan.
+4 more criteria

Exclusion Criteria

•Cohort B:
•Previous history of lung cancers.
•Symptoms suggestive of presence of current lung cancer, including (but not limited to): unexplained weight loss of over 15 pounds within the last 12 months or unexplained hemoptysis.
•Pregnant at time of enrollment.
•History of any type of cancer within 5 years, with the exception of in situ carcinomas and non-melanoma skin cancers (if excised).
•Current smoker.
•Smoked ≥ 20 pack years.
•Had a chest CT scan within 1 year of study entry.

Locations (1)

Chao Family Comprehensive Cancer Center University of California, Irvine

Orange, California, United States

Key Dates

Start Date

May 8, 2025

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2028

Last Updated

July 14, 2025

Enrollment

1,753

ESTIMATED participants

Conditions

Lung CancerDriver Mutation

Interventions

Low Dose CT Scan

DIAGNOSTIC_TEST

Contacts

Chao Family Comprehensive Cancer Center University of California, Irvine

CONTACT

1-877-827-8839 ucstudy@uci.edu

University of California Irvine Medical

CONTACT

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

RECRUITINGPHASE2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

Inclusion Criteria

Exclusion Criteria

Magnetic Resonance Imaging of the Lung: Oncological Applications

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance